Patents Assigned to ATTUNE PHARMACEUTICALS, INC.
  • Therapeutic inhibitory compounds
    Patent number: 11021463
    Abstract: Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: June 1, 2021
    Assignee: ATTUNE PHARMACEUTICALS, INC.
    Inventors: Andrew McDonald, Shawn Qian
  • Therapeutic inhibitory compounds
    Patent number: 10981893
    Abstract: Provided herein are heterocyclic derivative compounds of Formula (I) and pharmaceutical compositions comprising said compounds. The compounds of Formula (I) are useful for inhibiting plasma kallikrein. Furthermore, the disclosed compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: April 20, 2021
    Assignee: ATTUNE PHARMACEUTICALS, INC.
    Inventors: Andrew McDonald, Shawn Qian
  • Therapeutic inhibitory compounds
    Patent number: 10781200
    Abstract: Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: September 22, 2020
    Assignee: ATTUNE PHARMACEUTICALS, INC.
    Inventors: Andrew McDonald, Shawn Qian